Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Bernhard Dietzschold and Milosz Faber.
Connection Strength

2.609
  1. Faber M, Li J, Kean RB, Hooper DC, Alugupalli KR, Dietzschold B. Effective preexposure and postexposure prophylaxis of rabies with a highly attenuated recombinant rabies virus. Proc Natl Acad Sci U S A. 2009 Jul 7; 106(27):11300-5.
    View in: PubMed
    Score: 0.426
  2. Faber M, Faber ML, Li J, Preuss MA, Schnell MJ, Dietzschold B. Dominance of a nonpathogenic glycoprotein gene over a pathogenic glycoprotein gene in rabies virus. J Virol. 2007 Jul; 81(13):7041-7.
    View in: PubMed
    Score: 0.366
  3. Faber M, Pulmanausahakul R, Nagao K, Prosniak M, Rice AB, Koprowski H, Schnell MJ, Dietzschold B. Identification of viral genomic elements responsible for rabies virus neuroinvasiveness. Proc Natl Acad Sci U S A. 2004 Nov 16; 101(46):16328-32.
    View in: PubMed
    Score: 0.308
  4. Faber M, Pulmanausahakul R, Hodawadekar SS, Spitsin S, McGettigan JP, Schnell MJ, Dietzschold B. Overexpression of the rabies virus glycoprotein results in enhancement of apoptosis and antiviral immune response. J Virol. 2002 Apr; 76(7):3374-81.
    View in: PubMed
    Score: 0.257
  5. Schutsky K, Portocarrero C, Hooper DC, Dietzschold B, Faber M. Limited Brain Metabolism Changes Differentiate between the Progression and Clearance of Rabies Virus. PLoS One. 2014; 9(4):e87180.
    View in: PubMed
    Score: 0.149
  6. Schutsky K, Curtis D, Bongiorno EK, Barkhouse DA, Kean RB, Dietzschold B, Hooper DC, Faber M. Intramuscular Inoculation of Mice with the Live-Attenuated Recombinant Rabies Virus TriGAS Results in a Transient Infection of the Draining Lymph Nodes and a Robust, Long-Lasting Protective Immune Response against Rabies. J Virol. 2013 Feb; 87(3):1834-41.
    View in: PubMed
    Score: 0.135
  7. Li J, Ertel A, Portocarrero C, Barkhouse DA, Dietzschold B, Hooper DC, Faber M. Postexposure treatment with the live-attenuated rabies virus (RV) vaccine TriGAS triggers the clearance of wild-type RV from the Central Nervous System (CNS) through the rapid induction of genes relevant to adaptive immunity in CNS tissues. J Virol. 2012 Mar; 86(6):3200-10.
    View in: PubMed
    Score: 0.127
  8. Dietzschold B, Li J, Faber M, Schnell M. Concepts in the pathogenesis of rabies. Future Virol. 2008 Sep; 3(5):481-490.
    View in: PubMed
    Score: 0.100
  9. Li J, McGettigan JP, Faber M, Schnell MJ, Dietzschold B. Infection of monocytes or immature dendritic cells (DCs) with an attenuated rabies virus results in DC maturation and a strong activation of the NFkappaB signaling pathway. Vaccine. 2008 Jan 17; 26(3):419-26.
    View in: PubMed
    Score: 0.095
  10. Li J, Faber M, Papaneri A, Faber ML, McGettigan JP, Schnell MJ, Dietzschold B. A single immunization with a recombinant canine adenovirus expressing the rabies virus G protein confers protective immunity against rabies in mice. Virology. 2006 Dec 5-20; 356(1-2):147-54.
    View in: PubMed
    Score: 0.087
  11. Faber M, Bette M, Preuss MA, Pulmanausahakul R, Rehnelt J, Schnell MJ, Dietzschold B, Weihe E. Overexpression of tumor necrosis factor alpha by a recombinant rabies virus attenuates replication in neurons and prevents lethal infection in mice. J Virol. 2005 Dec; 79(24):15405-16.
    View in: PubMed
    Score: 0.083
  12. Faber M, Faber ML, Papaneri A, Bette M, Weihe E, Dietzschold B, Schnell MJ. A single amino acid change in rabies virus glycoprotein increases virus spread and enhances virus pathogenicity. J Virol. 2005 Nov; 79(22):14141-8.
    View in: PubMed
    Score: 0.083
  13. Faber M, Lamirande EW, Roberts A, Rice AB, Koprowski H, Dietzschold B, Schnell MJ. A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies. J Gen Virol. 2005 May; 86(Pt 5):1435-40.
    View in: PubMed
    Score: 0.080
  14. Dietzschold ML, Faber M, Mattis JA, Pak KY, Schnell MJ, Dietzschold B. In vitro growth and stability of recombinant rabies viruses designed for vaccination of wildlife. Vaccine. 2004 Dec 9; 23(4):518-24.
    View in: PubMed
    Score: 0.078
  15. Prosniak M, Faber M, Hanlon CA, Rupprecht CE, Hooper DC, Dietzschold B. Development of a cocktail of recombinant-expressed human rabies virus-neutralizing monoclonal antibodies for postexposure prophylaxis of rabies. J Infect Dis. 2003 Jul 1; 188(1):53-6.
    View in: PubMed
    Score: 0.070
  16. Dietzschold B, Faber M, Schnell MJ. New approaches to the prevention and eradication of rabies. Expert Rev Vaccines. 2003 Jun; 2(3):399-406.
    View in: PubMed
    Score: 0.070
  17. Kgaladi J, Faber M, Dietzschold B, Nel LH, Markotter W. Pathogenicity and Immunogenicity of Recombinant Rabies Viruses Expressing the Lagos Bat Virus Matrix and Glycoprotein: Perspectives for a Pan-Lyssavirus Vaccine. Trop Med Infect Dis. 2017 Aug 09; 2(3).
    View in: PubMed
    Score: 0.047
  18. Li J, Faber M, Dietzschold B, Hooper DC. The role of toll-like receptors in the induction of immune responses during rabies virus infection. Adv Virus Res. 2011; 79:115-26.
    View in: PubMed
    Score: 0.030
  19. Marissen WE, Kramer RA, Rice A, Weldon WC, Niezgoda M, Faber M, Slootstra JW, Meloen RH, Clijsters-van der Horst M, Visser TJ, Jongeneelen M, Thijsse S, Throsby M, de Kruif J, Rupprecht CE, Dietzschold B, Goudsmit J, Bakker AB. Novel rabies virus-neutralizing epitope recognized by human monoclonal antibody: fine mapping and escape mutant analysis. J Virol. 2005 Apr; 79(8):4672-8.
    View in: PubMed
    Score: 0.020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.